MAPT and Alzheimer disease: A controversial 2018 US framework proposed a “biological” definition, labeling anyone with biomarker evidence of amyloid accumulation as being on the “Alzheimer's continuum” and those positive for amyloid and tau to have “Alzheimer's disease”, even in the absence of clinical symptoms of dementia.3